FDA Approved Ionis' Genetic Disorder Drug
This is a news story, published by Yahoo, that relates primarily to U.S. Food and Drug Administration news.
drug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo news
For more news from Yahoo, you can click here:
more news from YahooAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
fat diet. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest triglycerides news, triglyceride levels news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Ionis PharmaceuticalsReuters
•US FDA approves Ionis Pharma's genetic disorder drug
79% Informative
U.S. Food and Drug Administration approves Ionis Pharmaceuticals' drug to treat a rare genetic disorder.
The drug, chemically known as olezarsen, is also the first approved treatment for familial chylomicronemia syndrome.
FCS is caused by the deficiency or impaired function of the lipoprotein lipase enzyme, responsible for breaking down triglycerides.
VR Score
87
Informative language
92
Neutral language
69
Article tone
formal
Language
English
Language complexity
62
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links